EUROIMMUN (part of Revvity) has added 23 new assays to its portfolio of indirect immunofluorescence assays (IFA) for use on the UNIQO 160, its all-in-one instrument for walkway IFA automation. The new assays extend existing panels for autoantibody diagnostics in rheumatology, vasculitis, hepatology and gastroenterology.
Cancer diagnostics laboratories have gained a powerful new tool in the fight against genomic complexity. Revvity has unveiled its first FDA-compliant IVD Mimix reference standards, engineered to revolutionise quality control in next-generation sequencing and droplet digital PCR workflows for oncology applications.
Cambridge-based biotechnology company CN Bio has enhanced its industry-leading drug-induced liver injury (DILI) assay with new animal microphysiological system models, enabling comparative toxicity studies across human, rat, and dog liver models to improve preclinical drug safety predictions.
BioSkryb Genomics and Tecan Group have unveiled an integrated single-cell multiomics workflow that promises to transform highthroughput cellular analysis. The partnership combines BioSkryb’s ResolveOME™ Whole Genome and Transcriptome Single-Cell Core Kit in 384-well format with Tecan’s Uno Single Cell Dispenser™, enabling parallel analysis of hundreds to thousands of individual cells whilst significantly reducing manual intervention.
Spring Bio Solution has unveiled NCE Grid, described as the world’s first free NCE-1 intelligence platform designed to decode and centralise Paragraph IV filing opportunities for generic pharmaceutical companies. The Somerset, New Jersey-based company launched the platform to address what it identifies as significant inefficiencies in current drug development intelligence gathering.
Swiss proteomics leader Biognosys has launched two major software updates that promise to revolutionise mass spectrometry-based protein analysis, with particular advances in immunopeptidomics research critical for therapeutic development.
Belgian biotech company Perseus Biomics has partnered with hardware developer Comate to launch MetaMAP, a compact automated system capable of delivering comprehensive gut microbiome analysis in 6.5 hours. The device addresses long-standing challenges in microbiome research by combining high-resolution bacterial identification with unprecedented speed.
Biotium has launched its ExoBrite™ CD9/CD63/CD81 Antibody Cocktails, targeting three widely utilised extracellular vesicle (EV) markers to simplify flow cytometry workflows in clinical laboratories and research settings. The new reagents promise enhanced signal quality whilst reducing optimisation requirements for multi-marker EV analysis.
Thermo Fisher Scientific has unveiled the Applied Biosystems™ MagMAX™ Pro HT NoSpin Plasmid MiniPrep Kit, a breakthrough automation solution designed to eliminate bottlenecks in small-scale plasmid DNA isolation. The system delivers high-quality results in under 35 minutes, addressing critical efficiency demands across therapeutic research applications.
Cambridge-based contract research organisation Metrion Biosciences has unveiled a breakthrough high-throughput screening assay targeting the Nav1.9 voltage-gated sodium channel, addressing a critical bottleneck in non-opioid pain therapeutic development. The validated assay platform promises to accelerate drug discovery programmes by overcoming traditional limitations that have hindered Nav1.9 research for years.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.